Opinion

Video

Patient Communication and Utilization of JAK Inhibitors in Atopic Dermatitis

An expert in the treatment of atopic dermatitis shares her perspectives on patient communication and treatment optimization practices.

Video content above is prompted by the following questions:

  • How do you educate and counsel patients who want to consider or are currently using a JAK inhibitor?
    • How do you discuss treatment targets and manage patient expectations?
  • What suggestions do you have for patients and healthcare professionals to optimize treatment of AD with JAK inhibitors?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.